Dr Mikkael Sekeres speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a phase 1b study evaluating glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML.
He explains that glasdegib is FDA approved in combination with low-dose cytarabine but that now this is the first time it is being used in combination with azacitidine, a drug that is far more commonly used.
Dr Sekeres reports that the response rates seen were comparable if not better to the combination of glasdegib and cytarabine.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.